^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TCEAL9 (Transcription Elongation Factor A Like 9)

    i
    Other names: TCEAL9, Transcription Elongation Factor A Like 9, WEX6, WBP5, Transcription Elongation Factor S-II Protein-Like 9, Transcription Elongation Factor A Protein-Like 9, WW Domain-Binding Protein 5, TCEA-Like Protein 9, DKFZp313K1940, Pp21 Homolog, WBP-5, WW Domain Binding Protein 5, WW Domain Binding Protein 1
    over1year
    Identifying a CD8T cell signature in the tumor microenvironment to forecast gastric cancer outcomes from sequencing data. (PubMed, J Gastrointest Oncol)
    A CD8T cell-related signature demonstrated robust prognostic predictive performance for GC. Our findings may reveal novel insights into the diagnosis and treatment of GC.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFA (Tumor Necrosis Factor-Alpha) • CLDN1 (Claudin 1) • ERRFI1 (ERBB Receptor Feedback Inhibitor 1) • TCEAL9 (Transcription Elongation Factor A Like 9) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • CD59 (CD59 Molecule) • GABARAPL1 (GABA Type A Receptor Associated Protein Like 1) • RGS2 (Regulator Of G Protein Signaling 2) • SOCS3 (Suppressor Of Cytokine Signaling 3) • ZFP36 (ZFP36 Ring Finger Protein) • TSC22D3 (TSC22 Domain Family Member 3)
    over3years
    Elevated TCEAL9 expression is correlated with trastuzumab-based neoadjuvant chemotherapy resistance in HER2-positive breast cancer (SABCS 2022)
    Objectives: To investigate the role of TCEAL9 in developing trastuzumab resistance in HER2-positive breast cancer A total of 83 patients who received paclitaxel, carboplatin and trastuzumab neoadjuvant chemotherapy in Fudan University Shanghai Cancer Center(FUSCC) from 2016 to 2018 were enrolled in this study...Overexpression of TCEAL9 was associated with lapatinib(IC50= 5.56 vs 10.90nM) and trastuzumab + pertuzumab(IC50= 745 vs 635nM) resistance in BT-474 and SK-BR-3 respectively, but has no influence in proliferation... TCEAL9 expression correlates with trastuzumab resistance and high TCEAL9 expression is associated with poor prognosis in HER2-positive breast cancer patients.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • TCEAL9 (Transcription Elongation Factor A Like 9)
    |
    HER-2 positive • TCEAL9 overexpression
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • lapatinib • Perjeta (pertuzumab)